Solid Biosciences’ Innovative Gene Therapy for DMD Earns Buy Rating from Analyst Joseph Schwartz

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on SLDB stock, giving a Buy rating on June 17.

Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Solid Biosciences’ innovative approach to gene therapy for Duchenne muscular dystrophy (DMD). The company’s SGT-003 therapy stands out due to its impressive results in early trials, showing unprecedented levels of microdystrophin expression in treated patients. This includes high expression levels measured by both Western blot and mass spectrometry, as well as a significant percentage of dystrophin-positive fibers.
Furthermore, Schwartz emphasizes the broader impact of SGT-003 on various biomarkers, which suggests potential for significant clinical improvements. Solid Biosciences is also making notable progress in patient dosing, with plans to treat at least 20 patients by the fourth quarter of 2025. The company is preparing for discussions with the FDA about accelerated regulatory pathways, which could further enhance its market position. These factors collectively underpin Schwartz’s optimistic outlook and Buy rating for SLDB.

According to TipRanks, Schwartz is a 5-star analyst with an average return of 10.1% and a 40.99% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Insmed.

In another report released on June 17, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $16.00 price target.